SUMMARY
Two recently published guidelines from national associations including the AABB, formerly the American Association of Blood Banks (Carson et al., 2016) , and the UK National Clinical Guideline Centre (NCGC) (Alexander & Cifu, 2016) suggest that a restrictive red blood cell (RBC) transfusion threshold of 7-8 g dL −1 for haemoglobin is safe in most clinical settings. In addition, the current AABB guidelines recommend a transfusion trigger of 8 g dL −1 for hospitalised patients with pre-existing cardiovascular disease (CVD), including those undergoing cardiac surgery. The AABB makes no recommendation for patients with acute coronary syndrome due to the lack of sufficient data from randomised clinical trials, whereas the NCGC recommends a threshold of 8 g dL −1 and a target value of 8-10 g dL −1 for this subset of patients.
Few trials of RBC transfusion triggers have focused on patients with underlying CVD. Most available data on transfusion practices for patients either with or without CVD stem from decades-old retrospective analyses of large electronic medical record databases (Yang et al., 2005; Alexander et al., 2008; Salisbury et al., 2011 Salisbury et al., , 2014 Sherwood et al., 2014; Magruder et al., 2017) . These studies compare nadir haemoglobin or haematocrit values among transfused and non-transfused patients with CVD without identifying the specific transfusion thresholds or clinical indicators used to justify RBC transfusion (Alexander et al., 2008; Salisbury et al., 2011) . The majority of studies do suggest that there is significant variability in transfusion practices among different centres (Hutton et al., 2005; Sherwood et al., 2014; Magruder et al., 2017) . However, no trials have investigated whether the risks of restrictive or liberal strategies differ in patients with CVD compared to those without known CVD or how these risks compare in CVD patients hospitalised for cardiac corrective procedures versus non-cardiac indications.
Two recent meta-analyses did summarise data evaluating transfusion thresholds in hospitalised patients with pre-existing CVD (Patel et al., 2015; Docherty et al., 29 March 2016) . One study found a significantly increased incidence of myocardial infarction but no significant mortality increase associated with a restrictive transfusion threshold in known CVD patients hospitalised for non-cardiac indications (Docherty et al., 29 March 2016) . The other study reported no significant increase in mortality with a restrictive strategy among CVD patients undergoing cardiac corrective procedures (Patel et al., 2015) . However, neither review directly addressed whether a restrictive strategy presents different risks in CVD compared to non-CVD patients or directly compared whether these risks differ in CVD patients admitted for a corrective cardiac procedure (e.g. coronary surgery) versus non-cardiac indications. These are important questions given that most guidelines still recommend restrictive RBC transfusion triggers for all patients, including those with or without known CVD, regardless of whether they are hospitalised for cardiac corrective procedures or not.
A single comprehensive analysis of the literature was performed to address these questions. We investigated whether the effects of restrictive or liberal transfusion policies on the incidence of myocardial infarction and acute coronary syndromes (major adverse coronary events, MACE) (Hirji et al., 2017) and mortality in CVD patients admitted for non-cardiac reasons were similar (main effect) or significantly different (qualitative interaction) compared either to patients without known CVD or to CVD patients having cardiac corrective procedures.
MATERIALS AND METHODS
We included all published randomised clinical trials comparing restrictive and liberal transfusion triggers that provided data on patients with and without known CVD admitted for non-cardiac reasons and all published randomised clinical trials comparing the two transfusion strategies in CVD patients having cardiac corrective procedures. We further divided the cardiac corrective procedures into two types: patients having cardiac coronary surgery bypass grafts and/or valve surgery as one type and those having percutaneous coronary interventions (PCI) as another. Trials were included if they enrolled and reported outcomes of patients with either known CAD (acute coronary syndrome or chronic ischemic heart disease) or other forms of CVD (including cardiac failure, valve disease and peripheral vascular disease). MACE (myocardial infarction or acute coronary syndrome) and mortality rates were the selected end-points of interest.
Literature search and study selection
We searched PubMed, EMBASE, Scopus, Web of Science and the Cochrane Central Register of Controlled Trials from database inception to 31 December 2017 without language restrictions for publications of randomised clinical trials comparing the use of a higher (liberal) and lower (restrictive) RBC transfusion trigger among adult patients with known CVD as well as without known CVD hospitalised for non-cardiac indications and those studies of CVD patients having corrective procedures, such as heart surgery or PCI. We also scanned the reference lists of analysed studies and references cited in reviews and guidelines identified in the searches.
To retrieve as much information as possible from all previous meta-analyses that included CVD patients, we requested any data regarding MACE or mortality not reported in the published studies from investigators [see S1 (Supporting Information) ].
Statistical analysis
Risk ratios of mortality and MACE were analysed using random effects models (DerSimonian & Laird, 1986) , with 0·5 added to each cell in the studies with zero cells. Heterogeneity among studies was assessed using the Q statistic and I 2 value (Higgins & Thompson, 2002) .
For the included trials enrolling both patients with and without known CVD, in order to assess differences in treatment effects between these two patient groups (i.e. interaction), we used two methods to account for the correlation within each study: (i) a 'one-step' approach with the study as a blocking factor; and (ii) a 'two-step' approach by first calculating the difference of log (RR) within each study and then combining them using a standard random effect model. These two methods gave almost identical results, so we only present the latter for better visualisation.
All analyses were performed using R version 3.4.3 (Angus et al., 1996 , R Development Core Team, 2017 . Traditional meta-analysis was performed using R packages meta version 4.9-0 (Schwarzer, 2015) and metafor version 2.0-0 (Viechtbauer, 2010). Two-sided P-values ≤0·05 were considered significant. The Bayesian meta-analysis was performed using R package bmeta version 0.1.2 (cran.r-project.org/web/packages/bmeta). We used RR with normal approximation. Random effect models with non-informative priors were used. Figure 1 shows a flowchart of study selection and enrolment. Seventeen randomised clinical trials met inclusion criteria. Nine included patients with and without known pre-existing CVD hospitalised for various non-cardiac indications [peripheral vascular surgery (Bush et al., 1997) , critical care (Hebert et al., 1999; Walsh et al., 2013) , orthopaedics (Carson et al., 2011; Parker, 2013; Gregersen et al., 2015) , septic shock (Holst et al., 2014) , surgical oncology (de Almeida et al., 2015) and acute upper GI bleeding (Jairath et al., 2015) ]. Six studies enrolled cardiac surgery patients (Bracey et al., 1999; Murphy et al., 2007 Murphy et al., , 2015 Hajjar et al., 2010; Shehata et al., 2012; Mazer et al., 2017) , and two enrolled PCI patients (Cooper et al., 2011; Carson et al., 2013) . Characteristics of the included studies are summarised in Tables 1 and S1 . Patients were enrolled from July 1994 through March 2017. These 17 studies enrolled 45-5243 patients each, for a total of 14 397 patients. Of these studies, nine provided data for 2048 patients with known CVD and 3337 without known CVD, all admitted for non-cardiac indications; six provided data for 7343 patients with CVD admitted for cardiac surgery; and two provided data for 154 patients with CVD admitted for PCI.
RESULTS

Study characteristics
Overall mortality and MACE risk in patients with pre-existing CVD admitted for non-CVD indications
Nine trials provided data on the mortality end-point. Among patients with known CVD hospitalised for non-CVD indications, there were 119 deaths among the 1032 CVD patients reported in the liberal transfusion group and 135 deaths among the 1016 CVD patients in the restrictive transfusion group (Fig. 2a) . There was no evidence of significant heterogeneity between studies for the mortality end-point (I 2 = 2·8%, P = 0·41). Overall, a liberal, compared to a restrictive, transfusion strategy produced a nominally but not statistically significant decreased relative risk (RR) of mortality (95% CI) in known CVD patients hospitalised for non-CVD indications
Four of the nine studies provided data on the MACE end-point in these known CVD patients admitted for non-CVD indications. MACE occurred in 19 of 729 CVD patients in the liberal transfusion group and 39 of 745 CVD patients in the restrictive transfusion group (Fig. 2b) . There was no evidence of heterogeneity across individual studies for the MACE end-point (I 2 = 0%, P = 0·91). A liberal compared to restrictive transfusion strategy was associated with a significantly decreased risk of MACE [0·50, (0·29-0·86), P = 0·01] among all patients with known pre-existing CVD hospitalised for non-CVD indications.
Subgroup analyses
Based on significant findings for MACE, we performed a sensitivity analysis to determine the consistency of the risk for both MACE and mortality across studies using lower and higher restrictive transfusion triggers. Figure 3 illustrates mortality and MACE end-points when the restrictive transfusion trigger was less than 8 g (∼7 g dL Other 'non-CABG category' contained non-pre-specified groups such as myxoma surgery.
Risk Ratio (RR) for Mortality (±95% confidence interval)
. in CVD patients. The decreased risk of mortality across the studies comparing a liberal trigger versus a restrictive trigger of ∼7 g dL −1 [0·87 (0·68-1·12), I 2 = 0%] and across studies comparing a liberal trigger versus a restrictive trigger of ∼8 g dL −1 [0·83 (0·49-1·42), I 2 = 23%] were each not statistically significant but were both similar to the overall decrease [0·90 (0·72-1·12)] (Fig. 3a) . The decreased risk of MACE in pre-existing CVD patients across the studies comparing a liberal trigger versus a restrictive transfusion trigger of ∼7 g dL [0·38 (0·09-1·53), I 2 = 0%] and across the studies comparing a liberal versus a restrictive trigger of ∼8 g dL −1 [0·53 (0·30-0·94)] was significant only for the latter (P = 0·03), but both were similar to the overall decrease [0·50 (0·29-0·86), I 2 = 0%] (Fig. 3b) .
Comparing MACE and mortality risks in patients with pre-existing CVD to those without known CVD For these studies, we then compared the overall RR of a liberal versus restrictive transfusion strategy on the primary end-points of MACE reported in four of the nine trials and death reported in all nine trials among patients with pre-existing CVD compared to those without known CVD. A liberal compared to a restrictive transfusion strategy reduced the RR of MACE in patients both with known CVD [2·6% vs. 5·2%; 0·50, (0·29-0·86)] and without known CVD (1·5% vs. 1·9%; 0·79, (0·39-1·58) in beneficial patterns that were similar (P = 0·30 for interaction, Fig. 4b ). In fact, the relative decreases in the risk of MACE using a liberal rather than a restrictive strategy in patients with versus without known CVD were remarkably alike (RR 0·50 vs 0·79, respectively) and had 95% confidence intervals that almost completely overlapped [CI (0·29-0·86) vs (0·39-1·58), respectively]. As expected, the absolute incidence of MACE among hospitalised patients managed with a restrictive strategy was much greater in those with pre-existing CVD compared to those without known CVD (5·2% vs 1·9% absolute incidence of MACE, respectively). However, a similar relative decrease in MACE was found by employing a liberal strategy despite these unsurprising differences in the absolute incidence of MACE. When examined over all patients from these four studies, whether they had known or unknown pre-existing CVD, a liberal compared to a restrictive transfusion strategy was associated with a significant decrease in MACE [0·59 (0·39-0·91), P = 0·02]. Conversely, among the nine studies reporting on the mortality end-point separately for patients with and without known pre-existing CVD and hospitalised for non-cardiac indications, the overall effect of a liberal strategy on mortality was significantly different and opposite depending on whether patients had known CVD or not (P = 0·05, qualitative interaction) (Figs 4a and S1). In patients randomised to a liberal strategy, mortality rates were lower among those with known pre-existing CVD (11·7% vs·13·3%, respectively) but higher in those without known CVD (19·2% vs 18·0%, respectively). The ratio (95% CI) of the RRs of death with a liberal strategy in patients with compared to those without known CVD was significant [0·73 (0·53-1·00), P = 0·05]. This divergent effect of a liberal strategy on mortality in patient with and without known CVD is at odds with its directionally similar effects on MACE.
MACE and mortality risks comparing patients with CVD hospitalised for non-cardiac indications versus cardiac corrective procedures including either cardiac surgery or PCI
The effect of a liberal versus restrictive transfusion strategy on mortality was not statistically significantly different (P = 0·26, interaction) in patients with CVD hospitalised for non-cardiac indications compared to those hospitalised for cardiac corrective procedures, including either PCI or cardiac surgery (Fig. 5b) . The RR of death was not statistically significantly decreased with a liberal strategy in patients with known CVD hospitalised for non-cardiac reasons [0·90 (0·73-1·11), P = 0·32] or for those having either PCI [0·26 (0·06-1·22), P = 0·09] or cardiac surgery [0·96 (0·74-1·24), P = 0·73]. Overall, however, among the 17 studies providing data for patients with CVD hospitalised for non-cardiac indications and for cardiac corrective procedures, a liberal strategy was associated with a nominal decrease in death that was not statistically significant [0·91 (0·77-1·07), P = 0·25].
There was a quantitative interaction for the effect of a liberal transfusion strategy on MACE comparing these three different CVD groups (P = 0·08 for interaction) that appeared ordered and prevented averaging over them (Fig. 5) . Specifically, a liberal strategy decreased the RR of MACE significantly in patients with CVD hospitalised for non-cardiac indications [0·50 (0·29-0·86), P = 0·01] and nominally in those with CVD having PCI [0·66, (0·24-1·83) P = 0·42] but not at all in those with CVD having cardiac surgery [0·98 (0·76-1·24), P = 0·84]. (0·56, 1·18), with an 83% posterior probability of the liberal strategy being better. The posterior estimate of RR for myocardial infarction (liberal vs restrictive) is 0·47 with 95% CrI (0·02, 9·87), with an 84% posterior probability of the liberal strategy being better.
Bayesian analysis
DISCUSSION
Seventeen randomised clinical trials enrolling 14 397 hospitalised patients provided data for 12 882 patients on the primary end-points examined here, either for patients with and without known CVD hospitalised for non-cardiac indications or for CVD patients hospitalised for cardiac corrective procedures. Four trials enrolled patients with pre-existing CVD hospitalised for non-cardiac reasons and provided MACE data. Among the 1474 patients included, a liberal transfusion trigger was associated with a 50% decrease in the risk of MACE. This effect was consistent independent of whether a restrictive threshold of ∼7 or ∼8 g dL −1 of haemoglobin was studied. This effect was also similar (I 2 = 0%, P = 0·91) for these patients regardless of the setting (critical care, orthopaedics, septic shock and surgical oncology). These four trials also included patients without known underlying CVD, and among these 1853 patients, a liberal transfusion strategy similarly decreased the RR of MACE. In addition to these four trials of non-cardiac hospital settings, we found six trials including CVD patients hospitalised for corrective cardiac procedures, including either PCI (two trials) or cardiac surgery (four trials). When comparing the effect of a liberal transfusion strategy in CVD patients between trials of non-cardiac hospitalisations and those for corrective cardiac procedures, the benefit on MACE was statistically significant for non-cardiac settings, but only nominally so for PCI patients and not at all significant for cardiac corrective surgery patients. Correcting the CVD abnormality with PCI or surgery may decrease or nullify the benefit of a liberal transfusion strategy on MACE during any hospitalisation.
Overall, in nine trials including 1949 patients with pre-existing CVD hospitalised for non-cardiac indications compared to 3337 admitted without known CVD, the effect of a liberal transfusion trigger on mortality was significantly different and opposite (P = 0·05, qualitative interaction). A liberal transfusion trigger increased mortality in patients without known CVD but decreased mortality in those with pre-existing CVD. To explain these unexpected and opposite effects on mortality, it appears likely that some additional and independent adverse survival effect of a liberal strategy was predominately affecting patients without known CVD. This adverse effect was sufficient to reverse the potential beneficial effect on mortality expected from decreasing MACE. These findings are consistent with results from the Transfusion in Critical Care trial (TRICC) for mortality in patients with and without severe CVD managed with either a liberal or restrictive strategy (Hebert et al., 2001; Deans et al., 2007) . In the TRICC trial, younger and healthier patients who were less likely to have CVD and would not normally be transfused during usual care had the greatest fold increase in mortality in the liberal versus the restrictive arm. Lastly, comparing patients with CVD hospitalised for non-cardiac indications versus cardiac interventions, a liberal strategy had a nominally beneficial effect on mortality rates, but this difference was not statistically significant.
Two studies in this meta-analysis had a combined weight of over 70%. One was a large multicentre transfusion trigger trial, enrolling more than 2000 orthopaedic surgery patients (Carson et al., 2011) . One of the most rigorously conducted Restrictive RBC transfusion triggers with CVD 343 studies to date using this methodology, this trial found a significant increase after 30 days in the incidence of MACE among orthopaedic patients with CVD who were treated with a restrictive strategy (J. Carson, personal communication) . The second publication (Mazer et al., 2017 ) studied more than 5000 cardiac surgery patients and found that higher transfusion triggers were not associated with meaningful differences in the risks of MACE and mortality. Taken together, these data support the notion that, for patients with chronic CVD requiring hospitalisation for a serious non-cardiac problem, the risk of MACE may be reduced by maintaining haemoglobin levels >9·5 g dL −1 . In contrast, if a CVD patient is admitted for correction of a cardiovascular abnormality with surgery, maintaining higher haemoglobin levels does not appear to be beneficial. Determining with any certainty whether there is any benefit to a liberal strategy during less-invasive cardiac corrective procedures such as PCI is hampered by insufficient data. There were only two trials enrolling 155 patients providing data on this question. However, one of these trials showed a significant increase in mortality with a restrictive strategy (Carson 2013) .
We recognise limitations to the interpretation of these data. We excluded trials not specifying inclusion of patients with CVD and trials in which requests for data on CVD patients were made but not provided or not available. This could have led to unrecognised selection bias. As discussed above, after the enrolment period of studies for our meta-analysis ended, a very large cardiac surgery trial studying transfusion triggers in over 5000 patients was published (Mazer et al., 2017) . Due to the influential nature of this trial, we reopened enrolment until December of 2017 with another search. Thus, this analysis is not prospective but retrospective. Other limitations include the following. The specific transfusion thresholds and the definitions of CVD and acute coronary syndrome varied between studies. Even though effect sizes were determined within trials first, and combined effects were determined, this may have had unrecognised consequences. Some of the outcomes analysed from specific trials were not primary or pre-specified end-points. In addition, some of the subgroups examined were not prospectively stratified in trials and were not part of an original randomisation scheme. Therefore, the data analysed here should be considered hypothesis-generating, rather than definitive. However, the importance of these data rests less on the definitive nature of the individual findings than on their consistency.
In patients both with and without known pre-existing CVD and admitted for non-cardiac indications in these studies, the decrease in the RR of MACE with a liberal versus a restrictive strategy was similar across different reasons for hospitalisation, regardless of whether a restrictive strategy used a haemoglobin threshold of 7 or 8 g dL −1 . Moreover, the overall point estimates we examined were always on the side of increased mortality and MACE rates for a restrictive transfusion trigger, regardless of whether the patient was admitted for non-cardiac reasons, PCI or cardiac surgery, although the benefit was minimal or non-existent for mortality and MACE in patients hospitalised for cardiac surgery. From 17 trials, we obtained 26 individual estimates in this analysis for risk of death and MACE with a restrictive versus liberal transfusion strategy (see Fig. 5 ). Of these 26 estimates, 21 favoured a liberal strategy and 5 a restrictive strategy. No study to date has found a restrictive transfusion strategy to be significantly beneficial in CVD patients, and at least two studies (Carson et al., 2011 (Carson et al., , 2013 and one other meta-analysis (Docherty et al., 29 March 2016) found that a liberal strategy was significantly beneficial in CVD patients not undergoing cardiac surgery.
To determine probabilities for the significant adverse effect of a restrictive strategy on MACE in patients with pre-existing CVD hospitalised for non-cardiac indications, we performed a Bayesian analysis. The probability that a restrictive strategy is worse than a liberal one was 84% for MACE and 83% for mortality. These findings are based on nine studies enrolling thousands of patients with and without known CVD. Likewise, a recent meta-analysis of transfusion trigger trials examining older hospitalised patients (>65 years old) likely to be at increased risk for CVD reported a significant increase in 30-and 90-day mortality with a restrictive transfusion strategy (Simon et al., October 2017) . Nevertheless, an appropriately designed prospective, large multicentre transfusion trial of patients with known pre-existing CVD or at high risk for CVD and admitted for non-cardiac procedures would be needed to provide definitive evidence and determine best transfusion practices. Risks in such a study could be minimised by enrolling only patients cared for by physicians who currently approve of and/or use a restrictive RBC transfusion strategy in CVD patients or by including only centres with policies mandating restrictive strategies in CVD patients.
The present study supports transfusion guidelines that recommend restrictive rather than liberal transfusion strategies for CVD patients undergoing cardiac corrective procedures. There are insufficient data to make such a recommendation for less-invasive cardiac procedures such as PCI. In contrast, for hospitalised patients admitted for non-cardiac reasons with pre-existing CVD or at high risk for CVD, clinicians should be reluctant to adopt restrictive transfusion strategies until prospective studies provide additional information.
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